US4511351A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Parenteral delivery system utilizing a hollow fiber cellular unit
Assignee: Alza Corp
•
Filing: 1984-05-14
•
Granted: 1985-04-16
•
Expires: 2004-05-14
Abstract
Abstract A formulation cell consisting essentially of a hollow fiber surrounded by a beneficial agent is disclosed for use in an intravenous delivery system. An intravenous system is disclosed that uses the formulation cell.
Inventors
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 12:53
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407; A61M5/1409
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
194 words
A method for administrating a beneficial drug to a warm-blooded animal, which method comprises the steps of: (a) introducing into the animal a delivery member in fluid communication with an intravenous delivery system, which system comprises: (1) a reservoir of a pharmaceutically acceptable fluid; (2) a formulation cell in fluid communication with the reservoir, which formulation cell comprises: (i) a wall that surrounds a lumen; (ii) an inlet in the wall for admitting a fluid into the lumen; (iii) a spiral wound module in the lumen, said module comprising a permselective membrane wound around a hollow fiber; (iv) a beneficial drug in the lumen in the space formed by the interior surface of the formulation cell and the exterior surface of the formulation cell and the exterior surface of the module; (v) an outlet in the wall for letting a fluid drug formulation leave the formulation cell, (b) admitting fluid into the formulation cell for contacting the drug in the space that passes into the spiral wound module for entering the hollow fiber to flow from the formulation cell; and, (c) administering the fluid drug formulation flowing from the formulation cell to the animal.
Claim 2
Independent Claim
194 words
A method for administrating a beneficial drug to a warm-blooded animal, which method comprises the steps of: (a) introducing into the animal a delivery member in fluid communication with an intravenous delivery system, which system comprises: (1) a reservoir of a pharmaceutically acceptable fluid; (2) a formulation cell in fluid communication with the reservoir, which formulation cell comprises: (i) a wall that surrounds a lumen; (ii) an inlet in the wall for admitting a fluid into the lumen; (iii) a spiral wound module in the lumen, said module comprising a permselective membrane wound around a hollow fiber; (iv) a beneficial drug in the lumen in the space formed by the interior surface of the formulation cell and the exterior surface of the formulation cell and the exterior surface of the module; (v) an outlet in the wall for letting a fluid drug formulation leave the formulation cell, (b) admitting fluid into the formulation cell for contacting the drug in the space that passes into the spiral wound module for entering the hollow fiber to flow from the formulation cell; and, (c) administering the fluid drug formulation flowing from the formulation cell to the animal.
Claim 3
Dependent Claim
116 words
A parenteral delivery system for administering a beneficial agent to a recipient, the delivery system comprising: (a) a reservoir of a medically acceptable fluid; and, (b) a formulation cell in fluid communication with the reservoir, the formulation cell comprising: (1) a wall that surrounds a lumen; (2) an inlet in the wall for letting fluid into the lumen; (3) a spiral wound module in the lumen, said module comprising a permselective membrane wound around a hollow fiber; (4) a beneficial agent in the space formed by the inside surface of the formulation cell and the outside surface of the module; and (5) an outlet in the wall for letting a drug formulation leave the formulation cell.
Claim 4
Dependent Claim
116 words
A parenteral delivery system for administering a beneficial agent to a recipient, the delivery system comprising: (a) a reservoir of a medically acceptable fluid; and, (b) a formulation cell in fluid communication with the reservoir, the formulation cell comprising: (1) a wall that surrounds a lumen; (2) an inlet in the wall for letting fluid into the lumen; (3) a spiral wound module in the lumen, said module comprising a permselective membrane wound around a hollow fiber; (4) a beneficial agent in the space formed by the inside surface of the formulation cell and the outside surface of the module; and (5) an outlet in the wall for letting a drug formulation leave the formulation cell.
Claim 5
Independent Claim
206 words
A method for administering a beneficial drug to an animal, which method comprises: (a) introducing into the animal a delivery member in fluid communication with an intravenous delivery system, which system comprises: (1) a reservoir of a medically acceptable fluid; (2) a primary path in fluid communication with the reservoir and the delivery member; (3) a circumventing path that permits a fluid to bypass the primary path, said circumventing path comprises: (a) a formulation cell, which formulation cell comprises: (i) a wall that surrounds an internal lumen; (ii) an inlet in the wall for letting fluid into the lumen; (iii) a spiral wound module in the lumen, the module comprising a permselective membrane wound around a hollow fiber; (iv) a beneficial drug in the lumen in the space between the module and the inside surface of the wall of the lumen; (v) an outlet in the wall for letting fluid and drug leave the formulation cell; (b) admitting fluid into the formulation cell for contacting the drug to form a fluid drug formulation that passes into the spiral wound module for entering the hollow fiber for flowing from the formulation cell; and, (c) administering the fluid drug formulation flowing from the formulation cell to the animal.
Claim 6
Independent Claim
206 words
A method for administering a beneficial drug to an animal, which method comprises: (a) introducing into the animal a delivery member in fluid communication with an intravenous delivery system, which system comprises: (1) a reservoir of a medically acceptable fluid; (2) a primary path in fluid communication with the reservoir and the delivery member; (3) a circumventing path that permits a fluid to bypass the primary path, said circumventing path comprises: (a) a formulation cell, which formulation cell comprises: (i) a wall that surrounds an internal lumen; (ii) an inlet in the wall for letting fluid into the lumen; (iii) a spiral wound module in the lumen, the module comprising a permselective membrane wound around a hollow fiber; (iv) a beneficial drug in the lumen in the space between the module and the inside surface of the wall of the lumen; (v) an outlet in the wall for letting fluid and drug leave the formulation cell; (b) admitting fluid into the formulation cell for contacting the drug to form a fluid drug formulation that passes into the spiral wound module for entering the hollow fiber for flowing from the formulation cell; and, (c) administering the fluid drug formulation flowing from the formulation cell to the animal.
Claim 7
Dependent Claim
143 words
A parenteral delivery system for administering a beneficial agent to a recipient, the delivery system comprising: (a) a reservoir of a medically acceptable fluid; (b) a primary fluid path in fluid communication with the reservoir; (c) a circumventing path that permits a fluid to circumvent the primary path, said circumvention path comprising: (1) a formulation cell, the cell comprising: (i) a wall that surrounds a lumen; (ii) an inlet in the wall for letting fluid into the lumen; (iii) a spiral wound module in the lumen, the module comprising at least one membrane that permits the passage of fluid and agent wound about a hollow fiber; and, (iv) a beneficial agent in the lumen in the space defined by the inside of the wall and the module; and, (v) an outlet in the wall for letting drug and fluid exit the formulation cell.
Claim 8
Dependent Claim
143 words
A parenteral delivery system for administering a beneficial agent to a recipient, the delivery system comprising: (a) a reservoir of a medically acceptable fluid; (b) a primary fluid path in fluid communication with the reservoir; (c) a circumventing path that permits a fluid to circumvent the primary path, said circumvention path comprising: (1) a formulation cell, the cell comprising: (i) a wall that surrounds a lumen; (ii) an inlet in the wall for letting fluid into the lumen; (iii) a spiral wound module in the lumen, the module comprising at least one membrane that permits the passage of fluid and agent wound about a hollow fiber; and, (iv) a beneficial agent in the lumen in the space defined by the inside of the wall and the module; and, (v) an outlet in the wall for letting drug and fluid exit the formulation cell.
Claim 9
Dependent Claim
99 words
A formulation cell for use with an intravenous delivery system, the formulation cell comprising; (a) a wall that surrounds an internal lumen; (b) an inlet in the wall for letting fluid enter the lumen; (c) a spiral module in the lumen, said module comprising at least one membrane that permits the passage of fluid and a beneficial agent spiral wound around a hollow fiber; (d) a beneficial agent acceptable for intravenous delivery in the cell between the wall and the space surrounding the module; and, (e) a outlet in the wall for letting agent and fluid exit the module.
Claim 10
Dependent Claim
99 words
A formulation cell for use with an intravenous delivery system, the formulation cell comprising; (a) a wall that surrounds an internal lumen; (b) an inlet in the wall for letting fluid enter the lumen; (c) a spiral module in the lumen, said module comprising at least one membrane that permits the passage of fluid and a beneficial agent spiral wound around a hollow fiber; (d) a beneficial agent acceptable for intravenous delivery in the cell between the wall and the space surrounding the module; and, (e) a outlet in the wall for letting agent and fluid exit the module.
References Cited (Backward Citations)
US2954028A
Cited
US3001525A
Cited
GB982107A
Cited
US3305446A
Cited
CH497181A
Cited
US3322114A
Cited
US4061141A
Cited
US3993073A
Cited
US3854480A
Cited
US3797494A
Cited
US3995631A
Cited
US3797485A
Cited
US3756237A
Cited
US3760984A
Cited
US3948254A
Cited
US3756390A
Cited
US3845770A
Cited
US3921636A
Cited
US4177256A
Cited
US3848603A
Cited
US3921635A
Cited
US3941126A
Cited
US3993072A
Cited
US3976068A
Cited
US4203439A
Cited
US4323457A
Cited
US4217894A
Cited
US4233973A
Cited
US4256104A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-15 | 1988-10-15 | 1989-04-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-15 | 1992-10-15 | 1993-04-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-15 | 1996-10-15 | 1997-04-16 | $7700.00 | Window Closed / Lapsed |